NCNMGF
AVIR icon

Nano-Cap New Millennium Growth Fund’s Atea Pharmaceuticals AVIR Stock Holding History

Nano-Cap New Millennium Growth Fund’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$163K Buy
35,000
+2,500
+8% +$12.4K 0.13% 115
2026
Q1 		$175K Sell
32,500
-17,500
-35% -$80.4K 0.16% 118
2025
Q4 		$179K Buy
+50,000
New +$159K 0.15% 125

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nano-Cap New Millennium Growth Fund's AVIR Position: Q2 2026 in Review

Nano-Cap New Millennium Growth Fund increased its Atea Pharmaceuticals (AVIR) stake by 7.7% in Q2 2026, buying an estimated $12.4K and bringing the position to 35,000 shares worth $163K. The position accounts for 0.13% of the portfolio, ranked #115.

Nano-Cap New Millennium Growth Fund first reported a position in AVIR in Q4 2025 and has held it in 3 quarters since. The position peaked at $179K in Q4 2025. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Nano-Cap New Millennium Growth Fund held 35,000 shares of Atea Pharmaceuticals worth $163K as of Q2 2026.
  • Nano-Cap New Millennium Growth Fund bought 2,500 Atea Pharmaceuticals shares in Q2 2026, an estimated $12.4K.
  • Atea Pharmaceuticals made up 0.13% of Nano-Cap New Millennium Growth Fund's portfolio in Q2 2026, its #115 holding.
  • Nano-Cap New Millennium Growth Fund first reported a position in Atea Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Nano-Cap New Millennium Growth Fund's Atea Pharmaceuticals position peaked at $179K in Q4 2025.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Nano-Cap New Millennium Growth Fund's 13F filing for Q2 2026, filed 14 Aug 2026.